Marathon Pharmaceuticals, LLC. – Duchenne muscular dystrophy

Access Program Information

<p>The <span class=”hit_inf”>expanded access</span> program will provide <span class=”hit_inf”>access</span> to treatment with <strong>Deflazacort</strong> in children, adolescent, and adult patients with <em>DMD</em> <em>(Duchenne&nbsp;Muscular&nbsp;Dystrophy)</em>&nbsp; in the U.S. who are ineligible, unable, or otherwise unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new drug application is under preparation and review. Enrollment is open to all eligible patients.</p>